| Product name | sitagliptin phosphate monohydrate |
| CAS No. | 654671-77-9 |
| Purity | 99% |
| Appearance | White powder |
| Application | Organic intermediates |
| Package | Plastic bags |
| Storage | Store in a closed container in a cool and dry place, below 5ºC. |
| Retest Date | 2 years |
Function of Sitaglipti phosphate monohydrate
Sitaglipti phosphate monohydrate is primarily used in the treatment of type 2 diabetes. Sitaglipti phosphate monohydrate works by inhibiting the enzyme DPP-4, which is responsible for breaking down incretin hormones like GLP-1 (glucagon-like peptide-1) and GIP (gastric inhibitory polypeptide). These hormones play a crucial role in regulating blood sugar levels by stimulating insuli secretion and inhibiting glucagon release from the pancreas. By increasing the availability of these hormones, sitaglipti helps lower postprandial (after meal) blood glucose levels, thus providing better glycemic control. Sitaglipti phosphate monohydrate is often used as an adjunct to diet and exercise to improve blood glucose levels in adults with type 2 diabetes. Sitaglipti phosphate monohydrate is commonly prescribed either as monotherapy or in combination with other antidiabetic agents, such as metformin, sulfonylureas, or insuli. Sitaglipti phosphate monohydrateis well-tolerated, with a low risk of causing hypoglycemia (low blood sugar) compared to other antidiabetic medications. In addition to its glucose-lowering effects, sitaglipti may have potential benefits for cardiovascular health, with ongoing studies investigating its effects on heart disease in diabetic patients. Sitaglipti phosphate monohydrate may also contribute to improved beta-cell function, which is essential for insuli production. Overall, sitaglipti phosphate monohydrate offers a safe and effective treatment option for managing type 2 diabetes.
